Patients, policymakers, and payors continue to look toward health technology assessment (HTA) as an important tool in helping define what constitutes “value” in health care. This debate has evolved in recent years, with a robust discussion around how these assessments are conducted and used in practice. But with this discussion has come a stark realization that HTAs are not just neutral tools. Their outputs reflect important methodological choices that can enhance – or detract from – patients’ equitable access to health care. Panelists will explore how these choices can drive health equity, what can be done to improve on some of the HTA methods used today, and discuss the importance of transparency in HTA so that all stakeholders can fully understand their impact on coverage and reimbursement decisions.